<code id='8BCEC38034'></code><style id='8BCEC38034'></style>
    • <acronym id='8BCEC38034'></acronym>
      <center id='8BCEC38034'><center id='8BCEC38034'><tfoot id='8BCEC38034'></tfoot></center><abbr id='8BCEC38034'><dir id='8BCEC38034'><tfoot id='8BCEC38034'></tfoot><noframes id='8BCEC38034'>

    • <optgroup id='8BCEC38034'><strike id='8BCEC38034'><sup id='8BCEC38034'></sup></strike><code id='8BCEC38034'></code></optgroup>
        1. <b id='8BCEC38034'><label id='8BCEC38034'><select id='8BCEC38034'><dt id='8BCEC38034'><span id='8BCEC38034'></span></dt></select></label></b><u id='8BCEC38034'></u>
          <i id='8BCEC38034'><strike id='8BCEC38034'><tt id='8BCEC38034'><pre id='8BCEC38034'></pre></tt></strike></i>

          knowledge

          knowledge

          author:fashion    Page View:71935
          Medicare and money photo illustration.
          Adobe

          Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier. 

          CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

          advertisement

          “I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more
          Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.
          Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

          RichardDrew/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsl

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          More regulation could be coming for drug ads

          AdobeWASHINGTON—Governmentregulatorsmaysoondecidewhethertocrackdownondistractingvisualsintelevisiond